CAMCOLIT

This brand name is authorized in Hong Kong SAR China, Ireland, Malta, Netherlands, Singapore, South Africa, UK.

Active ingredients

The drug CAMCOLIT contains one active pharmaceutical ingredient (API):

1	Lithium UNII 2BMD2GNA4V - LITHIUM CARBONATE
	Little is known about the way the lithium ion can modify neurotransmission within the CNS. Many of the proposed mechanisms have suggested an inhibitory effect on components of various neurotransmitter signalling pathways, such as cyclic AMP formation, cyclic GMP formation, G-proteins or inositol phosphate metabolism.
	Read more about Lithium

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CAMCOLIT Film-coated tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05AN01	Lithium	N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AN Lithium
Discover more medicines within N05AN01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
GB	Medicines & Healthcare Products Regulatory Agency	27548, 398587, 399363
HK	Department of Health Drug Office	66420
MT	Medicines Authority	AA1173/07301
NL	Z-Index G-Standaard, PRK	2283
SG	Health Sciences Authority	01305P
ZA	Health Products Regulatory Authority	L/1.2/0161